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Abstract  
     HIV-1 protease is a significant target for the development of inhibitory drugs for the 
treatment of HIV-1. Inhibitors that have been designed to the shape of the active site have been 
shown to be potent inhibitors of protease activity.  In order to expose the active site to the 
substrate, HIV protease displays significant movement in the flap region of the protease due to 
hydrophobic sliding.  It has been proposed that by establishing a disulfide bridge in this region of 
the protease the conformational flexibility of the flap region to expose its active site will be 
restricted. To this end, a cysteine and alanine mutant has been created to test the feasibility of 
disulfide bridge formation in the flap regions. This study establishes that the single alanine and 
single cysteine mutations in the flap region do not affect the folding or binding ability of the 
protease significantly. 
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1.0 Introduction  
1.1 HIV History and Population Overview 
 Human immunodeficiency virus (HIV) claimed the lives of two million people in 
2007, with another thirty-three million estimated to be infected by the World Health 
Organization
1
.  The United States Center for Disease Control estimated that there were over a 
million people infected in the United States at the end of 2006
2
.   
AIDS (Acquired Immunodeficiency Syndrome) was recognized for the first time in the 
late 1970s, when patients with severe immunologic dysfunctions began to emerge; by 1983 
scientists at the Pasteur Institute had isolated the HIV virus from patients with AIDS
3
. However, 
it was not until 1984 that Robert Gallo demonstrated that AIDS was caused by a retrovirus 
4
. In 
1986 the retrovirus was named HIV and the distinction between HIV-1 and HIV-2 had been 
made 
3
.   The difference between these two viruses arises solely from their species of origin, 
HIV-1 originated from the chimpanzee simian immunodeficiency virus (SIV), while HIV-2 
originated from the corresponding virus in the feral sooty mangabey monkey
3
. This is 
substantiated by the similarities in the genomes and phylum of the two viruses, along with 
abundance of the virus in the monkeys and possible routes of transmission 
5
. The realization that 
the virus had crossed over from monkeys in the region of Africa lead to the sequencing of twenty 
different simian immunodeficiency viruses and the discovery that the virus is non-pathogenic in 
its natural host
3
. The earliest documented case of HIV-1 was identified by a blood sample taken 
in 1959 from a man in the Democratic Republic of Congo. This evidence along with genetic 
analysis has lead scientists to propose that the virus entered the human population sometime 
around 1930 and that there have been several crossover events into the human population 
5
.  
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 Phylogenetic analyses of HIV-1 have led to the identification of distinct viral groups; 
these groups are named M (Main group), O (Outlier group), and N (the non-O and non-M 
group)
5
.  The M- group virus is the most prevalent globally and contains eleven clades, or 
clusters of genetic subtypes of the virus named A through K along with their circulating 
recombinants. Together they consistent of 95% of the world’s cases of HIV (see Figure 1)3.   
Clade B virus is the most widely researched virus because of its prevalence in the United States 
and Europe where the primary research on HIV is occurring. Interestingly, the more prevalent 
subtypes in Africa and Asia, while affecting more people are less researched. 
6
  The wide 
diversity of the virus contributes to recombination between subtypes when someone is coinfected 
with two or more subtypes of the virus resulting in circulating recombinant forms of HIV, or 
CRFs. Scientists have been studying these CRFs to track the spread of the virus.  
 HIV is a retrovirus which is classified as a lentivirus. This virus is characterized by its 
long incubation period before infection becomes evident. Also, it is unique in that it has a 
cylindrical or conical core. Most lentiviruses have genomes that express gag, pro, pol genes; 
however, HIV expresses many more proteins than the average lentivirus which contributes to its 
virulence 
3
.  
1.2 HIV Genome  
 The RNA genome of HIV (see figure 5) is different from that of other retroviruses that 
contain only three genes (gag, pol, and env).  HIV, in addition, to these encodes fifteen proteins 
and contains the genes  nef, vif, vpu, vpr, tat, rev,  along with an open reading frame near the 3’ 
long terminal repeat that codes for a super antigen
3
.   The gag, pol, and env genes encode for the 
viral packing proteins. The nef gene encodes for the nef protein, this protein plays a role in down 
regulating the cell surface molecules CD4, MHC-I, and MHC II, along with the env and vpu 
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proteins 
3
.  It has also been observed to enhance viral infectivity in comparison to the nef-deleted 
virus 
3
.  The vif gene has been observed to increase the viral infectivity factor by aiding virus 
assembly; this is indicated by experiments with viruses with a vif mutated virus which results in 
altered core assembly
3
.  The vpu gene is unique the HIV-1 virus, it enhances viral release and the 
degradation of CD4 cells.
3
  The vpr gene has been observed to enhance the transcription of the 
genome by encoding the nuclear localization sequence and arresting the host cell in the G2 phase 
of the cell cycle which is important because the lentivirus replicates in nondividing cells
3
.  The 
tat and rev genes encode for HIV regulatory proteins where tat stimulates transcriptional 
processivity by assembling transcription complexes and promoting the phosporylation of RNA 
pol II and rev promotes the nuclear export intron-containing RNA 
3
.    
  The HIV is a psuedodipliod, meaning that is there are two ssRNA strands in the virion, 
and only one will be used as the functioning provirus 
3
.  When cells are coinfected with subtypes 
of HIV, the RNA that are packaged into the virion can recombinate to from a new CRF.  This is 
packaged with the help of the non-coding region of the Gag-polyprotein which interacts with 
four RNA stem loops to create the core encapsidation signal, then the RNA associates and is then 
packaged with the Gag-polyprotein which will autocatalyze to form the necessary replication and 
assembly enzymes integrase, protease, reverse transcriptase
3
.     
1.3 HIV Life-Cycle  
The HIV life cycle consists of the binding and fusion of the virus with the cell membrane 
and reverse transcription of the ssRNA. This continues to the integration of the newly 
synthesized DNA into the host DNA, transcription and translation of the DNA to RNA then to 
protein, the assembly of the proteins, and budding of the new virus (See Figure 3).   
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The binding and fusion of the virus to the host cell is mediated by the Env glycoproteins 
located on the surface of the virus.  Glycoprotein120 (gp120) binds to CD4 cells with high 
affinity on the cell surface, these cells are immunologically important for their interactions with 
T-cell lymphocytic MHC-II receptors 
3.7
. The HIV gp120 and gp41 bind to the CD4 receptor 
with high affinity encouraging the fusion of the cell and viral surfaces
3
. The fusion of the two 
does not occur unless the chemokine coreceptors CCR5 and the CXCR4 bind to the viral protein 
3
. In some individuals a mutation in the inherited alleles of theses coreceptors has led to 
resistance against the HIV-1 virus 
3
.  
 The direct fusion of the two surfaces leads to the introduction of viral subparticles in the 
cytoplasm of the host cell; this event initiates the reverse transcriptase of HIV.  The HIV reverse 
transcriptase does not operate with high fidelity leading to five to ten base pair errors in the HIV 
genome for every round of replication 
8
.  After the RNA has been processed to dsDNA, it is 
transported to the nucleus for integration into the host chromosome by integrase.  During this 
process the new DNA is associated with a pre-integration complex (PIC); this complex is 
transported to the nucleus with the DNA by the Vpr protein contained in the PIC 
3
.  HIV-1 is 
unique among retroviruses because of the selectivity with which it integrates into the actively 
expressed regions of the chromosome. This selectively has been attributed to PIC and is likely 
one of the many factors involved in the level of virulence of HIV-1
3
. Contributing to the 
promotion of the replication of the HIV DNA are the HIVs long terminal repeats that include 
eukaryotic enhancers and promoters for RNA pol II.  
After the mRNA has been assembled into proteins by ribosomes the resulting Pol and 
Gag-Pol polyprotein must be processed by the HIV-1 protease.  The resulting proteins are 
matrix, nucleocapsid and, capsid proteins, and p6; these proteins assemble to make the structural 
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components of the virus
3
.  The proteins receive the encapsidation signal from the interaction of 
the four RNA stem loops and the Gag polyprotein.  
Once the virus is encapsulated by the protein p6, which promotes the incorporation of 
accessory proteins into the virus and with the endosomal sorting proteins in the cell promotes the 
release of the virus from the plasma membrane 
3
.  When the virion is released from the cell its 
new surface membrane is that of the host cell plasma membrane. This is where the virion uptakes 
many of the cellular surface proteins along with the Env proteins that were expressed in the ER 
and incorporated into the plasma membrane prior to the budding process
3
.  The mature virus 
contains a conical core with ssRNA and Gag-Pol proteins ready to infect another cell. 
 HIV vpu protein associates with CD4 molecules in the endoplasmic reticulum and 
promotes the degradation of the molecule allowing for the transport of Env to the cell surface for 
viral packaging
7
.  In addition the nef and vpu proteins down regulate the surface expression of 
MHC proteins, which would normally present viral epitopes for recognition by cytotoxic T-
cells
7
. By degrading the CD4 receptor and suppressing MHC expression the virus can essentially 
hide in the body while slowly destroying the host immune system.  The depletion of CD4 cells in 
the body eventually leads to Acquired Immunodeficiency Syndrome or AIDS.    
1.4 Targeting HIV Treatment 
 The main targets for HIV treatments occur at major events in the HIV life cycle.  The list 
of available inhibitors include: fusion inhibitors, reverse transcriptase nucleoside and reverse 
transcriptase non-nucleoside inhibitors, protease inhibitors, and integrase inhibitors. In addition 
there are various pioneering efforts being made to develop a vaccine against HIV; however, 
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these have been met with limited or no success, leaving the option of preventing the disease 
untapped.  
 The high rate of replication and error prone reverse transcriptase of the HIV provide a 
pathway for the creation of mutant forms of the virus and its components. However, it should be 
noted that in untreated patients the wild-type protease is the most prevalent. In response to 
treatment over 50% of patients in the U.S. receiving anti-retroviral therapy express resistance to 
at least one of the available anti-retroviral drugs 
9
. This also brings concerns that the transmission 
of drug resistant HIV will become prevalent.  The variability of the virus has lead to a 
comprehensive course of treatment incorporating the use of multiple anti-retroviral drugs, mainly 
a mixture of reverse transcriptase and protease inhibitors, nicknamed HAART or highly active 
anti-retroviral therapy 
9
.  HAART therapy focuses on targeting the reverse transcriptase and the 
protease of the virus, creating a situation where the virus is forced to mutate at multiple sites to 
become resistant
9
.  The success of the therapy is limited due to the fact that mutations will slowly 
arise and the treatment will need to be altered or the patient will experience treatment failures 
9
.  
Nucleoside and nucleotide analog reverse transcriptase inhibitors were the first 
antiretroviral drugs approved by the Food and Drug Administration for the treatment of HIV in 
1987
10
. The drug is structurally similar to the nucleic acid and so competes with the natural 
nucleic acid as a substrate 
10
. The inhibition is achieved by replacement of the 3’ hydroxyl group 
of the analog, making the phosphodiester linkage required for elongation of the strand impossible 
10
.The non-nucleoside analog reverse transcriptase inhibitors directly bind to the reverse 
transcriptase and are non-competitive inhibitors of the enzyme 
10
. They work to block the DNA 
polymerase activity by binding to the hydrophobic domain next to the catalytic site of the 
enzyme 
109
.   
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As mentioned before, the glycoproteins 41 and 120 play a role in the fusion of the viral 
and cellular membrane. Upon binding to the CD4 and CCR5 two peptide motifs are formed 
called heptad repeats, these two motifs unite to form a six-helix bundle which pulls the virus into 
the cell
10
. The only FDA approved fusion inhibitor is called enfuvirtide and interrupts the 
formation of this bundle of heptads to prevent the fusion of the viral and cellular membranes 
10
. 
This has provided drug experienced patients with some success in treatment. However, due to the 
intensive process to make the peptide drug is quite expensive compounded by the fact that it is 
administered twice a day and that most patients will experience a rash at the injection site, the 
cost-effectiveness of the drug remains a large factor in its use.  Treatments with protease and 
transcription inhibitors are preferable to fusion inhibitors no only because of their cost, but their 
relative effectiveness. To date, the treatments for HIV that focus on targeting HIV protease have 
not only proven to be successful but there is a wide selection available.   
The role of HIV protease in the maturation of the human immunodeficiency virus verifies 
it as a target for inhibitors with the aim of arresting the development of the virus. There are 
currently nine protease inhibitors available on the market that have been approved by the United 
States Food and Drug Administration 
11
.  These drugs are competitive inhibitors for the active 
site of the protease and all of the inhibitors, save one, are peptidometics 
11
.  This means that the 
inhibitor can mimic the transition state of the substrate, but the peptide cannot be cleaved by the 
protease due to its hydroxyethylene or hydroxylethylamine core 
11
. Hence the enzyme is 
inhibited.   
The emergence of HIV protease inhibitors on the market also brought about the 
emergence of mutations in the protease that were negatively selected  by the virus to disrupt 
inhibitor binding while maintaining the enzyme function 
12
. These mutations of the protease that 
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affect inhibitor binding can also affect substrate specificity. Therefore the selective pressure is 
present for the substrate of the protease to co-evolve with the enzyme
13
.  In this respect it has 
been shown that the non-active site mutations are more abundant and occur later than active site 
mutations; however, these mutations play a larger role in lowering the affinity of inhibitors while 
stabilizing enzyme-substrate binding
14
.   The protease recognizes several sites along the gag-pol 
polyprotein and it has been observed that the most thermodynamically favorable inhibitors have 
the same volume and shape as the substrate cleavage sites. This has led to a method of a structure 
driven drug design for HIV protease inhibition.  
1.5 HIV Protease Substrate Envelope Hypothesis: Structure Driven Design  
Structure driven design of HIV protease inhibitors is based on the observation that the 
substrates of the protease have a rather uniform shape, despite their differing constituents 
12
. The 
border of the volume they occupy has been coined the “substrate envelope” 12.  It has been 
observed that when the consensus volume of the bound inhibitors differs greatly from the 
substrate volumes that clinically relevant mutations have occurred in the areas where the 
inhibitors have protruded from the substrate envelope 
12
. This has lead to the formation of the 
“substrate envelope hypothesis” that an inhibitor which fits the substrate envelope will resist 
clinically relevant mutations, and the mutations that do arise would not only reduce the affinity 
of the inhibitor but also the substrate, making viable escape mutations unlikely
1516
.  Using this 
hypothesis to facilitate a structure based drug design approach; researchers of HIV protease have 
been able to analyze the binding interactions among protease and inhibitor. The success of the 
inhibitor darunavir in treatment experienced patients has been attributed to how well it fits in the 
substrate envelope 
16
.   
15 
 
1.6 Structure and Functions of the HIV Protease 
HIV protease (see Figure 4) is a homodimer of a consisting of two ninety-nine amino 
acid monomers produced by the pol gene that recognizes and cleaves sites in the gag-pol and gag 
polyproteins
17
. The cleavage of these polyproteins as indicated in section 1.3 is essential to the 
life-cycle of HIV.  Each monomer contributes one conserved aspartic acid (D25) to the substrate 
active site, which is a pocket formed within the interface of the two monomers with the opposing 
aspartic acid residues necessary for cleavage opposite each other at the base of the active site
18
. 
When the molecule is dimerized it works as an aspartyl protease using the aspartic residues to 
cleave ten sites non-homologous sites along the polyprotein
18
. The flaps of the protease are 
flexible and are known to play a role in the binding of substrates and inhibitors by using this 
flexibility to accommodate substrates 
19
.  
The binding and cleavage of the substrates by the HIV protease is mediated by water 
molecules that facilitate the action via acid- base catalysis 
18
. The water molecule donates a 
proton to the carboxyl groups of the aspartic acid and the proton is then transferred to the 
corresponding peptide bond completing the cleavage 
18
. Upon binding to the substrate the 
protease undergoes a large conformational change 
17
.  HIV protease is a symmetric enzyme that 
recognizes substrates with asymmetric charge distribution and size 
17
. The protease creates 
different binding surfaces for these substrates where there are at least eight residues that bind to 
the substrate prior to cleavage 
17
.   Within the active site of the protease all the residues of the 
either adjust to the substrate without binding to it or have Van der Waals interactions that are 
mediated by water molecules positioned between the substrate and protease
17
. It has also been 
observed that the α-carbons of the active site residues do not shift; however, the rotation of the 
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side-chains and rearrangement of water molecules within the site alter facilitate the binding of 
the substrate residues
17
. 
1.7 Hydrophobic Sliding in HIV Protease 
 Forty of the ninety-nine residues of HIV protease are hydrophobic; a number of the 
residues line the active site or the flap region of the protease 
20
.  These hydrophobic residues aid 
in the conformational changes that occur with HIV-1 protease by exchanging Van der Waals 
contacts and maintaining structurally significant hydrogen bonds throughout the conformational 
changes involved in opening the flap region of the protease
21
. While these residues are outside 
the active site they mutate along with active site mutations. The mutation of protease residues 
outside the active site occurs because non- active site mutations help stabilize the protease while 
the active site mutations decrease structural integrity 
14
. In this way the mutations assist the 
protease in developing less affinity to the inhibitor while sacrificing little loss of affinity towards 
the substrate. Most mutations that occur in the hydrophobic core of the protease are mutations to 
other hydrophobic residues; this leads researchers to conclude that the hydrophobic interactions 
in the core are important to HIV-1 protease function 
21
.   
 To assess the contributions of non-active site mutations on the overall function of the 
protease is important to understand exactly how they play a role in the movement of the protease. 
Engineering disulfide bridges into the protease is a proposed method to lock the protease in a 
particular conformation allowing for an analysis of how protease motion contributes to catalytic 
activity.  In the non-active site of HIV-1 protease there are residue sites where the α carbon to α 
carbon and β carbon to βcarbon distances are favorable for the position of cysteines to form a 
disulfide bond. To provide a comprehensive background for this type of research it is necessary 
to establish the effect of substituting the original residue with another. Using alanine mutagenesis 
17 
 
to substitute the original residue with an alanine eliminates the side chain of the residue past the 
β carbon and should not alter main-chain conformation, or impose extreme electrostatic or steric 
effects
22
. By analyzing the effect of this substitution on the overall catalytic activity of HIV-1 
protease a better comparison of the effect of the engineered cysteine substitutions can be made.  
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2.0 Methods 
2.1 Expression of HIV Protease  
For the amplification of the HIV-1 protease with the mutations of interest Z-competent 
BL21 (DE3) E. coli cells with a pET-11a plasmid vector (Novagen) were induced with 0.33mM 
IPTG (isopropyl-beta-D-thiogalactoside) when the absorbance at 600nm was 0.5.     
 During expression the protease aggregates in inclusion bodies. To lyse these bodies the 
cells were resuspended using elution buffer 1 ( pH 8.0; 20mM Tris pH 7.5, 1mM EDTA, 10mM 
DTE, 51.4mg lysozyme, 50μL 0.2PMSF in isopropanol ) per pellet and let it sit on ice for 30 
minutes. A cell disrupter was used to lyse the cells; the cells were then spun in Oakridge tubes 
for 30 minutes at 20000g. The cells were resuspended in 20mL of elution buffer 2 ( pH 8.0; 
20mM Tris pH 7.5, 1mM EDTA, 10mM DTE and 2M Urea). The cells are centrifuged for 30min 
at 20000g and resuspended in 20mL of elution buffer and spun for 30 minutes at 20000g twice 
and treated with elution buffer (pH 8.0; 20mM Tris pH 7.5, 1mM EDTA,7M guanidine) for one 
hour one ice. The protein was dialyzed against the elution buffer overnight at 4⁰C with two 
changes of buffer.  
2.2 Purification   
 20mL of the protease protein was loaded onto a G-75 Sphedex column in 50% acetic acid 
at a flow rate of about 3mL/hour.  Using refolding buffer (50mM Sodium Acetate pH5.5, 10% 
glycerol, 5% ethylene glycol, 5mM DTT) the protease was refolded using a rapid dilution 
technique involving a peristaltic pump slowly dripping the protease into a beaker of refolding 
buffer at 0⁰C and overnight dialysis at 4⁰C.  After the dialysis was complete the protein was 
concentrated using a 2μ Amicon concentrating device until the absorbance at 280nm was greater 
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than 1.5.  Additionally the protease was purified by fast liquid protein chromatography, to 
remove contaminants from the solution.  
2.3 Crystallization 
 Protein at a concentration of 1.5mg/mL was incubated with three times excess of 
darunavir at room temperature for 30 minutes. Using the hanging drop method the tray with a 
protease-darunavir concentration of 1.2mg/mL in a buffer of 50mM sodium phosphate 
7%DMSO and 30-41% ammonium sulfate yielded crystals.  
2.4 Crystal Harvesting and Diffraction 
 A crystal was identified and collected using a Hampton loop and submerged in a cryogen 
of glycerol and 30% of crystallization buffer to prevent the buildup of ice under the cryostream. 
The crystal was diffracted using an R-Axis IV image plate mounted on a Rigaku rotating anode 
at -80
o 
, a total of 200 3-minute frames were collected using a 1
o
 oscillation.   
2.5 Diffraction Data Processing 
Model building was completed using COOT
23
 and CCP4i
24
. The diffraction data was 
processed and a molecular replacement model made using the aMoRe function.  The figure was 
refined at a sigma value of 1.0 using COOT with data adjustment in Refmac5 for several rounds 
of refinement.  
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3.0 Results  
 As a first step in obtaining protein for crystallization BL21 (DE3) z-competent E. coli 
cells were transformed with the plasmid of choice provided by the Schiffer lab. The next step in 
the protocol was to amplify the transformed cells in a large scale expression over a three hour 
period. In Figure 6A an SDS-PAGE gel stained with coomassie is depicted. In lane one a sample 
of the cells is visualized without IPTG induction, the next three lanes represent specific one hour 
intervals after cell induction. Comparing these samples to a purified HIV protease marker shows 
that the induction with IPTG produced a robust expression of HIV protease. The band that is 
protease is referred to by an arrow and shows significant expression one hour after induction.  
During expression the protease aggregated into inclusion bodies and in order to harvest 
the protease from the cells it was necessary to use a cell press along with the denaturing protocol 
assigned in the methodology. Following this step it was necessary to purify the protein from the 
remaining cellular debris, this was done by running the protease through a 50% acetic acid 
column. This step yielded several fractions over the length of the purification process that 
contained protease. These were run on an SDS-PAGE gel using a kaleidoscope marker and were 
stained with coomassie to determine if they were pure (Figure 6 panel B). The resulting gel 
showed one size band for all fractions indicating that the protease collected was pure enough to 
continue with the protocol.   
During extraction from the cells the protease had been denatured and in order to continue 
the protease was refolded using a rapid dilution system. Once refolded, the protease was further 
purified by fast liquid protein chromatography (FPLC). This step ensures that the protease used 
for crystal trials is not contaminated with any other proteins. To further produce crystals the 
protein needs to be in a stable complex with substrate or inhibitor, to accomplish this protease 
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was incubated in three times excess of darunavir. To form crystals the protease darunavir 
complex is mixed with a salt buffer in a drop hung above a well with the same buffer this is 
called the hanging drop setup.  
 To identify the best set of conditions for crystallizing this mutant in crystal trials multiple 
buffer conditions and concentrations of protease were tested. Interestingly it was found that 
regardless of whether or not the protease had been purified by FPLC that the protease formed in 
a concentration of 1.2 mg/mL of protease and darunavir in a buffer of 50mM sodium phosphate 
and 30-40% ammonium sulfate (Figure 7). Once the crystallization conditions were identified by 
the formation of protease crystals it was then possible to harvest crystals for data collection by x-
ray diffraction. Due to the size and availability of crystals formed from the protease that had not 
been purified by fast liquid protein chromatography, the crystal that was collected for analysis 
here was not from a condition using FPLC purified protein.  
 In order to obtain a diffraction pattern for the crystal devoid of extra water the crystal was 
submerged in a cryogen before diffraction at -80
o
C to prevent ice build-up. The resulting 
diffraction data was resolved using CCP4i and COOT. This revealed that that the space group of 
the collected protease crystal was P212121, this describes the unit cell as a primitive lattice with 
three perpendicular twofold screw axes (Table 1). This group spacing along with the cell 
parameters for a, b, and c (51.98Å, 57.38Å, and 60.68Å respectively) is consistent with other 
HIV protease-substrate complexes commonly found in literature. 
 In order to have a starting structure for the experimental data a molecular replacement 
solution was created using CCP4i’s aMoRe feature. To further elucidate the structure several 
rounds of refinement in COOT followed by data adjustment in Refmac5 were employed.  To 
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ensure that the experimental data were in line with the human and computer refinement it was 
necessary to compute the Rwork and Rfree values of the structure, these were obtained using 
Refmac5. These values give a statistical representation of the agreement between experimental 
and manipulated data (Table 1). The G16C, L38A mutant data yielded a structure that did not 
differ from the overall structure of the wild type protease (Figure 8). The protease was modeled 
with 121 water molecules and two sodium molecules and appears to have the usual 
conformations for the flap region and the active site.   
To draw more significant conclusions about the overall differences in the conformation of 
this mutant it was compared with 1T3R, an HIV protease mutant close to the wild type with only 
the catalytic aspartic residues mutated to asparagines that had been incubated with darunavir.   
Comparison with this structure revealed that there is a disagreement in the conformation of the 
protease in the flap region. Several factors that may be responsible for this change include that 
there was a general lack of density in the area of residues 36-42, and that this crystal is not from 
a protein sample that had been purified by fast liquid protein chromatography, meaning that 
contaminates could have disrupted the x-ray diffraction and data processing.  
 In order to identify the cause and extent of the disruption in protein folding the residues 
in the area of interest are highlighted in Figure 10 along with the corresponding residues in from 
1T3R. This leads to the observation that the mutations of the G16C, L38A protease (Table 2) 
seem to have disrupted protein folding in the flap region of the protease.  These changes may 
also be due to the movement seen in this area of the protease or simply due to a poor quality of 
the crystal. However, without more data available there is no conclusive answer as to the reason.  
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 The binding of inhibitor reveals that the overall catalytic activity of the protease has been 
conserved in this mutant. To ensure the feasibility of the formation of a disulfide bridge in the 
flap region between the 38
th
 and 16
th
 residues, the 38
th
 alanine was mutated by computer 
simulation to a cysteine and distance measurements taken (Figure 11A). Initial measurements in 
space indicate that the lengths from sulfur to sulfur and from sulfur to β-carbon were about 
3.58Å and 4.40Å not favorable for formation of a disulfide bridge. Due to the flexibility of the 
side chain of the cysteine amino acid further computer manipulation in space finds a favorable 
conformation of the 38
th
 residue for the formation of a disulfide bond with the 16
th
 residue. These 
residues are situated at the outer regions of the protease and would theoretically keep the flap 
area of the protease in a closed conformation, precluding it form binding to either substrate or 
inhibitor.   
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4.0 Discussion 
  By creating mutations that affect the functionality of HIV protease it is possible to 
visualize the movement of the protease and assess contributions of specific residues to its 
stability and catalytic activity.  Previous studies have shown that non-active site mutations arise 
secondary to active site mutations and provide a mechanism for stabilizing the active site. In the 
treatment of HIV this means that the resistance to the HIV protease inhibitor drugs that develops 
overtime will become stronger as time lapses, making the need for new and better treatments of 
HIV a necessity.  
 In this study non-active site mutations were induced to explore the feasibility of disulfide 
bridge formation. The G16C mutation demonstrates that alteration to this area of the protease has 
insignificant effects on the structure of the protease. However, the mutation L38A causes a 
disruption in the region surrounding the flap region of the protease.  Closer examination revealed 
that there were no complementary sections between this structure and the wild type. Despite this 
disagreement in structure the catalytic site is still active, meaning that the proposed mutations to 
cysteines that will contribute to a disulfide bridge are favorable for our purposes. Computer 
simulation demonstrates that it is possible to expect a disulfide bond to form between the two 
residues. The goal here is to restrict the overall flexibility while conserving the catalytic activity 
of the protease.    
The flexibility of the protease is due to the large amount of hydrophobic residues in the 
flap region. While this flexibility would be challenged by the formation of a rather rigid disulfide 
bond, further mutation of the lysine 38 to a cysteine would be required to make a conclusive 
comment about the effect to function. This study provides the background for understanding the 
changes induced by creating the additional proposed mutations. The flap region would not have a 
normal conformation, however the active site would retain is function. This would produce a 
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desirable way to restrict protease function. This study shows that the formation of a disulfide 
bond is plausible, further studies would need to assess the effect of the responsible mutations 
concurrently in the protease to identify if they would indeed cause a restriction of the active site 
and prevent substrate access.  If the active site was not restricted by this disulfide bridge then the 
current thinking behind the mechanism for hydrophobic sliding would need to be re-evaluated. 
Current approaches to drug design could be augmented by a better understanding of this region 
and its movement. 
Due to the mechanism of hydrophobic sliding that occurs when the protease binds to 
substrate or inhibitor, there is some amount of thermodynamic energy being expended. If a 
protease mutant can be made with an engineered disulfide bond it would then be a model that 
could be used in the development of future protease drugs.  A peptide inhibitor that does not 
require the expended energy of protease movement for binding would present a more favorable 
target for the protease than current inhibitors. Such an inhibitor would create a more 
thermodynamically stable protease inhibitor complex than the substrate and perhaps lead to the 
effective inhibition of the protease.  
If this mechanism cannot be achieved then there are other HIV protease drug targets that 
can be examined for development, such as disrupting the hinge region of the protease by 
preventing dimer formation. Such a model would also inhibit HIV protease in vivio before it 
seeks out substrate or peptide inhibitors. Other areas that could be explored would include 
possibly using inhibitors to attract degradation complexes already present in the cell such as 
proteasomes. Such a mechanism could tether several ubiquinatin complexes to an inhibitor and 
signal the protease for degradation. Using such mechanisms that already exist in the cell could 
possibly provide a pathway for the development of treatments without incurring many side 
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effects. Another way that HIV can be targeted is through using the simian animal that it is comes 
from as a model for treatment. As mentioned earlier, the origin of HIV has been identified as 
coming from various monkey species in Africa. In these species it has been noted that SIV has 
no apparent immunological consequence, perhaps one day it will be possible to create a vaccine 
using their viral form and resistance to it as a basis for development.  
The wide effect of HIV on the population of the world (Figure 2) makes it a target for the 
development of drugs and community awareness for its treatment and prevention. The spreading 
awareness of HIV and methods for preventing the disease will decrease the spread of the disease. 
Regardless of the education and awareness of the population, the disease will continue to spread 
because many people do not know they have the disease until symptoms arise and continue to 
spread it until it is detected. Also as new, mutated forms of the virus are spread further inhibitory 
treatments will need to be developed until the point when a completely effective vaccine or 
treatment can be created.  Until that time it is imperative that research into HIV drug 
development continues.  
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5.0 Figures  
 
Figure 1 HIV Clades: The different clades of HIV around the world. Clade B is most prevalent 
in the United States and Europe and is therefore the most researched 
26
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Figure 2 Prevalence of HIV in 2007: The prevalence of HIV in the world among populations 
aged 15-49 in 2007, the regions with the highest prevalence of HIV are Africa and Russia 
27
. 
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Figure 3 HIV Life Cycle Diagram: This diagram shows the life-cycle of the HIV from fusion 
with the cell membrane to viral assembly and budding
28
.  
 
 
Figure 4 HIV Protease Schematic:  HIV protease complexed with a tripeptide inhibitor, shown 
here with the catalytic aspartic acid residues highlighted 
29, 30
. 
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Figure 5 Genomic Organization of HIV-1:  Schematic of the genome of HIV. 
 
 
 
 
Figure 6 Induction and Purification Gels: To the left, panel A, is the induction gel with a 
purified protease marker, e. Coli cells were induced with IPTG over a three hour period. The 
arrow points to the band of protease after one hour of expression, which already shows strong 
expression of the protease in this system. To the right, panel B. The harvested protease protein 
was denatured and run on a 50% acetic acid column. To the right is a gel of various protease 
samples collected during the purification with the kaleidoscope marker on the right, the samples 
are fairly well purified. 
 
 
 
Figure 7 HIV Protease Crystals: Picture of protease and darunavir crystals in the well of buffer 
before they were harvested for x-ray diffraction.  
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Figure 8 Obtained HIV Protease Structure: HIV protease with G16C and L38A mutations, 
displayed in ribbons. 
 
Figure 9 HIV Protease Comparision: Overlay of obtained HIV protease structure and wt-HIV 
protease complexed with darunavir (in magenta), notice the difference in conformation of the 
outer loops.  
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Figure 10 Overlay of Residues 35-42: Residues 35-42 of WT-protease and of the obtained 
structure overlaid the green strand is the wild type protease and the cyan is the obtained protease 
structure. The difference in side chain conformation may be due to the mutation of the 38th 
lysine to an alanine. Overall the overlay reveals that the conformation of this protease is different 
from the wild type.   
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Figure 11 Cysteines in the Disulfide Bridge: By computer imaging it is possible to mutate the 
38th residue from an alanine to a cysteine. Panel A is a measurement of the distance between the 
16
th
 and 38
th
 residues. The distance is 3.58Å from sulfur to sulfur and 4.40Å from sulfur to β-
carbon.  Further computer simulation finds a conformation favorable for the disulfide bond 
formation as seen in panel B.  
 
 
 
  
B 
A 
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6.0 Tables 
Table 1 Crystallographic Data Statistics: The following data was collected after refinement of 
the x-ray diffraction data and describes the obtained protease structure.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Mutations of the Protease: Mutations of the HIV protease construct as provided by the 
Schiffer lab are as follows, the two listed in bold are the mutations of interest for creating a 
disulfide bond.  
  
Space Group  P 21 21 21  
Cell parameters --------- 
a 51.98Å 
b 57.38Å 
c 60.68 Å 
Rwork % 17.40% 
Rfree%  22.00% 
RMS deviation from ideality  --------- 
Bonds (Angstroms) 0.0086 
Angle distance ( Angstroms) 1.265 
 reflections used 14074 
optical resolution 1.53 Å 
Overall β factor 28.2 Å2 
Q7K  
L33I  
L63I  
C67A  
C95A  
G16C  
L38A  
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